Brief answer
Human research on bioresonance does not yield a single conclusion. In some areas, randomized, double-blind, and placebo-controlled studies have reported positive clinical signals; in some areas, only small observational or mechanistic studies have been found; and for certain questions such as allergy diagnosis and atopic dermatitis, well-controlled studies have shown no positive results. For this reason, scientific evaluation should not be conducted through a single question such as “does bioresonance work?”, but rather through the question: in which indication, with which device/protocol, in which study design, and on which outcome was what found?
Evidence map
| Field | Study | Design / Sample | Main signal |
|---|---|---|---|
| Smoking cessation | Pihtili et al., 2014 | Double-blind, placebo-controlled RCT; n=190 | Higher quit rates in favor of the active group between 1 week and 1 year |
| Smoking cessation | Marakoğlu et al., 2024 | Real-world/clinical series; n=1272 | MORA widely used; p=0.132 in comparison with other methods |
| Depression | Muresan et al., 2021 | Three groups; n=140 | Positive change in Hamilton scores in groups receiving bioresonance |
| Functional GI complaints | Nienhaus & Galle, 2006 | Randomized placebo-controlled; n=20 | Change in symptom frequency/severity, stomach pain, and meteorism in favor of the active group |
| IBS + chronic low back pain | Barassi et al., 2024 | Pilot observational; n=20 | Positive change in BSFS, fecal calprotectin, and SF-36 parameters |
| Knee osteoarthritis | Maiko & Gogoleva, 2000 | Indexed as RCT; n=75 | Higher clinical response in the standard therapy + BRT group |
| Cervical pain | DRKS00017381 | Prospective, double-blind, placebo-controlled; final n=54 | Result in favor of the active group in NDI and VAS parameters in the sponsor final report |
| Hypothyroidism | Kiryanova et al., 2016 | Three comparative groups; n=50 | More pronounced change in certain thyroid/lipid parameters in the BRT group added to standard replacement |
| Type 2 diabetes | Kiryanova et al., 2017 | Three comparative groups; n=413 | Greater decrease in HbA1c/glucose/BMI parameters in the standard therapy + BRT group |
| Overtraining | 2018 PubMed publication | Active vs placebo; n=60 athletes | Positive changes in autonomic and blood pressure rhythm parameters |
| Rheumatic diseases | Schuller & Galle, 2007 | Partially placebo-controlled; n=15-21 | Change in certain measurements and perceived health status in favor of the active group |
| Rheumatoid arthritis | Islamov et al., 2002 | Mechanistic human study | Changes in lymphocyte antioxidant system |
| Fibromyalgia | Gogoleva, 2001 | Comparative clinical study; n=60 | Faster/higher clinical response reported in the manual therapy + BRT group |
| Oncological support | Kirsever et al., 2022 | Evaluation of prospective records; n=51 | Palliative symptom and quality-of-life signals; not an antitumor efficacy study |
| Allergy diagnosis | Lewith et al., 2001 | Double-blind randomized block; n=30 | Electrodermal test showed no concordance with skin prick results |
| Atopic dermatitis | Wüthrich et al. | Double-blind sham-controlled; n=32 children | No measurable superiority of active BIT demonstrated in addition to standard care |
1. Strongest positive signal: smoking cessation
The 2014 study is methodologically one of the most remarkable studies in the bioresonance literature. 190 cigarette smokers were divided into 95 active and 95 placebo groups; the study was conducted as prospective, double-blind, and placebo-controlled. Quit rates in the active group were reported as 77.2% versus 54.8% at 1 week; 51.1% versus 28.6% at 1 month; and 28.6% versus 16.1% at 1 year.
The 2024 data from Turkey present real-world follow-up of 1272 individuals. This study is valuable in terms of its large sample size, but it is not randomized controlled, and no statistically significant difference was found between MORA and other methods (p=0.132). When read together, these two studies highlight smoking cessation as one of the most researched clinical areas for bioresonance; larger independent RCTs nevertheless remain valuable.
2. Metabolic field: diabetes and thyroid
The type 2 diabetes study is one of the largest samples in the literature, with 413 individuals. All patients received standard diabetes therapy; 198 individuals were evaluated in the additional bioresonance group, 72 individuals in the standard therapy alone group, and 143 individuals in the standard therapy + sham procedure group. Greater reductions in HbA1c, fasting and postprandial glucose, urinary glucose, and BMI were reported in the active group. The hypothyroidism study is also a three-group design involving 50 patients in whom standard hormone replacement was maintained. These studies show that bioresonance has been investigated not as a replacement for standard metabolic therapies, but as an adjunct intervention.
3. Pain and musculoskeletal system
Human studies exist in the areas of knee osteoarthritis, fibromyalgia, and cervical pain. The gonarthrosis study has a sample size of 75 participants and a long follow-up; the cervical Rayocomp study is particularly of interest due to its double-blind sham device design. However, the primary details of the Rayocomp results are contained in the sponsor’s final clinical report; an independent peer-reviewed full publication would allow for a better assessment of the evidence quality.
4. Gastrointestinal field
Although the 2006 MORA study included only 20 individuals, it is randomized and placebo-controlled. The 2024 IBS-low back pain study, on the other hand, utilizes more up-to-date biomarkers and quality of life scales, but has an uncontrolled pilot design. Together, the two studies make the area of the gut-brain axis and functional symptoms interesting for future research.
5. Autonomic nervous system and athletic recovery
In a study examining 60 athletes with overtraining syndrome across active and placebo groups, favorable changes associated with parasympathetic effect, blood pressure variability, and circadian rhythm were reported. Today, retesting this hypothesis with HRV, sleep, and performance data would be particularly valuable.
6. Why are negative studies important?
Ignoring allergy diagnosis and atopic dermatitis studies distorts the scientific picture. The 2001 BMJ study demonstrated that electrodermal testing cannot differentiate between atopic and non-atopic individuals. In a sham-controlled pediatric study on atopic dermatitis, active application also failed to demonstrate additional clinical superiority. These results do not mean refuting all claims of bioresonance; they indicate which clinical questions require better validation.
How do we grade the evidence?
We look at study design rather than the number of studies. A double-blind sham-controlled RCT is stronger than an uncontrolled case series; a large sample size can be more reliable than a small sample size; independent replication is more convincing than a sponsor report. Furthermore, because devices and protocols differ from one another, results obtained with one device should not automatically be generalized to all other bioresonance systems.
Our approach at our Bodrum clinic
We define the objective for which bioresonance is used from the beginning and, whenever possible, track the response using objective or standardized criteria. In cases requiring a diagnosis, we continue to utilize laboratory tests, imaging, and relevant specialist evaluations. We aim to update this evidence map as new human studies are published.
Bioresonance main guide → | Bioresonance showcase →
Selected references
- Pihtili A, et al. Forsch Komplementmed. 2014;21(4):239-245. PMID: 25231565.
- Marakoğlu K, et al. Istanbul Med J. 2024;25(2):99-104. DOI:10.4274/imj.galenos.2024.84555.
- Muresan D, et al. J Med Life. 2021;14(2):238-242. PMID: 34104247.
- Nienhaus J, Galle M. Forsch Komplementmed. 2006;13(1):28-34. PMID: 16582548.
- Barassi G, et al. Medicina. 2024;60(7):1099. PMID: 39064528.
- Maiko OYu, Gogoleva EF. Ter Arkh. 2000;72(12):50-53. PMID: 11201834.
- German Clinical Trials Register DRKS00017381.
- Kiryanova VV, et al. Kazan Med J. 2016;97(4):545-550; 2017;98(3):334-337.
- PubMed PMID: 30499486; 17971670; 12511993; 11494446.
- Lewith GT, et al. BMJ. 2001;322:131-134. PMID: 11159567.
Written and medically reviewed by: Dr. Kerem Çağlayan
Last medical review: September 11, 2026
